Wei L, MacDonald T M, Watson A D, Murphy M J
Medicines Monitoring Unit, Division of Medicine & Therapeutics, Ninewells Hospital & Medical School, Dundee, UK.
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):385-92. doi: 10.1002/pds.1297.
There is considerable evidence that statins can reduce cardiovascular events. Currently high-risk patients are treated to a target cholesterol concentration. An alternative prescribing strategy (the 'fire-and-forget' approach) would instead deploy low-dose statins more widely. It has been suggested that for the same cost this approach might prevent more cardiovascular events. We have compared the treat-to-target and fire-and-forget statin prescribing strategies with respect to adherence and cardiovascular outcomes.
We used a population-based record-linkage database containing several data sets linked by a unique patient identifier. We identified two cohorts of patients. Patients in the treat-to-target cohort were prescribed a statin, and subsequent measurement of their cholesterol was followed by upward titration of their statin dose if necessary. Patients in the fire-and-forget cohort were prescribed a statin, but no further cholesterol measurement was observed during the follow-up period.
Adherence to statin treatment in patients treated to target was significantly better than in patients treated on a fire-and-forget basis (adjusted odds ratio 2.51, 95%CI 2.26-2.78). We found a lower cardiovascular disease (CVD) event rate in patients treated to target than in fire-and-forget patients (hazard ratio of CVD or cardiovascular death 0.41 (0.35-0.48) even after adjustment was made for adherence and baseline CVD risk).
Our findings suggest that adherence to statins is worse in patients treated on a fire-and-forget basis than in patients treated to a target cholesterol concentration, and that this prescribing strategy is associated with worse cardiovascular outcomes.
有大量证据表明他汀类药物可降低心血管事件风险。目前,高危患者接受治疗以达到目标胆固醇浓度。另一种处方策略(“一劳永逸”方法)则是更广泛地使用低剂量他汀类药物。有人认为,在成本相同的情况下,这种方法可能预防更多心血管事件。我们比较了达标治疗和“一劳永逸”他汀类药物处方策略在依从性和心血管结局方面的差异。
我们使用了一个基于人群的记录链接数据库,该数据库包含多个通过唯一患者标识符链接的数据集。我们确定了两组患者。达标治疗组的患者被处方了他汀类药物,随后测量其胆固醇水平,必要时对他汀类药物剂量进行向上滴定。“一劳永逸”组的患者被处方了他汀类药物,但在随访期间未观察到进一步的胆固醇测量。
达标治疗患者对他汀类药物治疗的依从性明显优于“一劳永逸”治疗的患者(调整后的优势比为2.51,95%置信区间为2.26 - 2.78)。我们发现,达标治疗患者的心血管疾病(CVD)事件发生率低于“一劳永逸”治疗的患者(即使在对依从性和基线CVD风险进行调整后,CVD或心血管死亡的风险比为0.41(0.35 - 0.48))。
我们的研究结果表明,“一劳永逸”治疗的患者对他汀类药物的依从性比达标治疗至目标胆固醇浓度的患者更差,并且这种处方策略与更差的心血管结局相关。